X-ZELL part of Galen Growth’s 2020 HealthTech Cohort
Singapore, May 2020 – X-ZELL is one of 23 start-ups selected to be part of Galen Growth’s inaugural HealthTech Cohort, an acceleration and networking initiative designed to champion healthcare innovation from across Asia.
According to Julien de Salaberry, CEO & Founder of Galen Growth, the world-first program has been “curated to grow a community of top start-ups in Asia, where great minds creatively disrupt and transform the current healthcare and health tech ecosystem.”
It will focus on enabling increased collaboration between start-ups, corporates and investors, connecting companies across industry segments and borders, as well as providing them with insights derived from Galen Growth’s vast health technology database.
During the official launch event, which took place via Zoom, de Salaberry explained that Galen Growth has long recognised the need for transformation in the healthcare industry and has been working closely with businesses to scale digital health innovation since 2015.
“We believe that our 23 selected start-ups possess some of the most promising potential to create societal value through their innovative solutions and talent in digital health powered by our unique program and network”.
Such value and innovation, he added, are in much higher demand amidst the rapidly changing healthcare and digital health landscape due to the current COVID-19 pandemic.
“Through this exclusive partnership program, Galen Growth will create a gateway for each member of the HealthTech Cohort to bring energy, experience, skills and creativity to build an extensive portfolio, leading to successful commercial traction and scale.”
Dr Sebastian Bhakdi, Founder & CEO of X-ZELL, welcomed the initiative, saying it would send the right signal to a volatile market: “We applaud Galen Growth on taking the lead during a time of uncertainty and empowering Asian health tech innovation at a global scale.”
He added, “We feel extremely honoured to be featured among some of the most exciting names in Asian health tech and look forward to making the most of the this exciting opportunity
“We would like to thank the team at Galen Growth – especially Julien de Salaberry, Hélène Champoux and Dario Heymann – for creating a new gateway to bring our energy, experience, skills and creativity to the next level alongside some of the most talented entrepreneurs in the industry.”
For more information on the 2020 HealthTech Cohort, click here.
About Galen Growth
Galen Growth is the leading market intelligence, analytics and advisory firm in the Asia Pacific health technology market, empowering Fortune 500 companies and global investors to fast-track growth strategies in a highly dynamic, $80+B start-up ecosystem. The company recently expanded to Europe and will soon also cover the North American market.
Recurrently ranked among the most innovative health technology start-ups in Asia, X-ZELL is fusing next-generation cell detection technology with cutting-edge Artificial Intelligence to isolate and visualise ultra-rare cells in blood and frozen tissue. Established in Bangkok, Thailand, the company recently made global headlines for successfully isolating and visualising tumour-associated Circulating Endothelial Cells (tCEC) from the blood of high-risk prostate cancer patients. Long considered undetectable in clinical routine, these ultra-rare cells help physicians diagnose clinically significant cancers early, when they can be cured – in turn avoiding more than 70 per cent of unnecessary interventions and saving billions to health systems worldwide. Now headquartered in Singapore, X-ZELL is aiming to make tCEC-based cancer screening accessible to patients around the globe – making the young company one of the promising names in the booming cancer prevention space.